Novel therapies for high-grade gliomas: A vision for future

Autor: G Kohanbash, C Belka, RE Coleman, D Barba, JH Kim, H Burris, E Razis, C Sturiale, Lesniak, SA Grossman, B Dhokia, MP Gustafson, ZQ Han, P Traxler, AM Sandmair, LM DeAngelis, G Franceschi, P Msaouel, G Kaur, MJ Zhu, S Taillibert, I Yang, M Brown, AT Bruce, HP Kalofonos, T Todo, TC Liu, HS Hochster, KL Black, C Royce, D Fukumura, NL Spector, P Duic, MP Sayers, M Koslow, C Stanton, KL Fink, L Kim, JM Reid, AK Muhammad, JS Yu, AH Friedman, T Gohongi, KA Kreuzer, R Cozens, GP Dunn, DA Haas-Kogan, KB Hymes, JH Sampson, DD Song, RB Herberman, R Ramina, K Kawakami, GG Gomez, N Jelluma, E Galanis, SC Saris, S Thomas, Sy Lim, FM Iwamoto, AJ Grant, H Bender, W Xia, C Wallace, LH Merchant, S Kunwar, RD Schreiber, RE Merchant, AM Kaplan, Vivek Tandon, JS Hardwick, K Ballman, Berger, I Stroud, D Fabbro, JM Piepmeier, WK Yung, JC Hiserodt, K Moore, YB Wang, L Zhang, R Alemany, N Dmitrieva, HJ Choi, KM Kroeger, CD Stiles, D Schiff, LJ Old, JL Clarke, AL Asher, DV Woo, JL Mahaley, R Brandt, P Clement, JI Kreisberg, M Ehtesham, FK Miura, EM Hiesiger, I Cokgor, PY Wen, IK Na, C Crane, LB Nabors, HI Robins, HT Chung, G Ibrahim, NK Kim, A Arista, K Panageas, S Ahmad, RK Jain, KL Penne, JJ Vredenburgh, GD King, M Weller, CT Kuan, T Tihan, H Wakimoto, R Sakalas, CW Reynolds, JC Buckner, S Lassiter, HF Young, M Kioi, H Fukuhara, J Wykosky, MA Vogelbaum, TN Kreisl, H Okada, RE McLendon, V Jendrossek, CJ Wikstrand, P Puranen, M Puranen, W Xiong, Mahaley, YY Kim, C Sauvageot, JA Quinn, SR Husain, S Labropoulos, IF Pollack, CH Tung, J Laterra, JM Dowell, HS Friedman, A Desjardins, EC Dees, K Shah, BK Cho, C Valiengo Lda, GC Gonzalez, P Forsyth, M Assenberg, W Debinski, P Riva, JC Rodrigues, DA Eberhard, S Xia, SM Chang, Jy Yoo, J Hardcastle, CA Kruse, TJ Liu, R Weissleder, Jr MahaleyMS, D Snook, W Roth, Subhashree Mahapatra, M Frattarelli, KC Wang, FF Lang, KA Jaeckle, EA Chiocca, K Terada, C Gomez-Manzano, PR Lowenstein, JJ Kelly, SA Rosenberg, P Selviaridis, Prados, IV Ulasov, E Tyminski, S Sinha, RL Hayes, J Brueggen, T Kuroda, GJ Baker, J Sul, G Simpson, M Rackover, SK Kim, DD Bigner, S Desideri, K Hopkins, XO Breakefield, JN Rich, H Ikeda, M Kawakami, JM Bruner, M Rosenfeld, ND Arvold, PH Aguiar, LW Brady, D Morris, G Roldan, M Candolfi, S Kesari, B Seed, BH Joshi, M Holdhoff, RL Martuza, YG Kwon, SX Jiang, JT Kemshead, M Campone, NL Vujanovic, Y Chen, DA Reardon, TF Cloughesy, A Dispenzieri, M van den Bent, M Kossila, B Hildebrandt, EH Oldfield, S Puri, T Zhang, K Kurozumi, S Loimas, MK Wibowo, C Holder, EM Rosen, H Hurwitz, G Dresemann, EC Kim, H Assi, BL Liu, N Butowski, C Appelt, Groves, EJ Moore, SJ Han, CA Palmer, N Ramakrishna, J Emrich, MJ Maurer, RK Puri, JL Norris, P Waterman, J Clarke, S Piantadosi, T Peery, JF Curtin, LE Abrey, AS Chi, N Courtenay-Luck, A Hemingway, Y Saeki, AB Lassman, V Papanastassiou, J Boni, ED Day, E Hussain, C Miyamoto, AK Mahapatra, R Scholz, AT Parsa, RB Greeno, KL Low, T Mikkelsen, S Chang, C Sarkar, J Fueyo, DV Cramer, PR Allegrini, A Dowlati, DM Gibo, L Xu, M Dey, MM Ames, M Shaffrey, HA McDonald, SB Omay, TR Pawlikowska, RL Hamilton, D George, N Riva, Ashok Kumar Mahapatra, A Immonen, TA Mattei, M Bamberg, X Ye, B Woodhall

Publikováno v: Indian Journal of Neurosurgery, Vol 01, Iss 01, Pp 054-060 (2012)

The treatment for high-grade glioma remains an enigma. The standard treatment using surgery, radiation therapy and chemotherapy for such highly malignant lesions has only yielded modest results, in terms of survival and improving the quality of life

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::831d1b23c52c18a1f1c51646572e45e9
http://www.thieme-connect.de/DOI/DOI?10.4103/2277-9167.94372

Human B Cells Mediate Innate Anti-Cancer Cytotoxicity Through Concurrent Engagement of Multiple TNF Superfamily Ligands.

Autor: Janjic BM; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States., Kulkarni A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, United States., Ferris RL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, United States.; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, United States., Vujanovic L; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, United States., Vujanovic NL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2022 Mar 22; Vol. 13, pp. 837842. Date of Electronic Publication: 2022 Mar 22 (Print Publication: 2022).

ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.

Autor: Yoneyama T; Department of Pathology, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA.; VAPHS, Pittsburgh, PA., Gorry M; Department of Pathology, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA.; VAPHS, Pittsburgh, PA., Sobo-Vujanovic A; Department of Pathology, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA.; VAPHS, Pittsburgh, PA., Lin Y; Department of Biostatistics, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA., Vujanovic L; Department of Medicine, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA., Gaither-Davis A; Department of Medicine, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA., Moss ML; BioZyme Inc, Apex, NC., Miller MA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA., Griffith LG; Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Lauffenburger DA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.; Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Stabile LP; Department of Pharmacology and Chemical Biology, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA., Herman J; Department of Medicine, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA., Vujanovic NL; Department of Pathology, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA.; Department of Immunology, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA.; VAPHS, Pittsburgh, PA.

Publikováno v: Journal of Cancer [J Cancer] 2018 Jun 23; Vol. 9 (14), pp. 2559-2570. Date of Electronic Publication: 2018 Jun 23 (Print Publication: 2018).

Soluble TNF Regulates TACE via AP-2α Transcription Factor in Mouse Dendritic Cells.

Autor: Ge L; Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232., Vujanovic NL; Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232; vujanovicnl@upmc.edu.; Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232; and.; VA Pittsburgh Healthcare System, Pittsburgh, PA 15261.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2017 Jan 01; Vol. 198 (1), pp. 417-427. Date of Electronic Publication: 2016 Nov 16.

Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells.

Autor: Sobo-Vujanovic A; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Munich S; Rush University Medical Center, Department of Neurosurgery, Chicago, IL, USA., Vujanovic NL; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Pathology, Pittsburgh, PA, USA; Department of Immunology, Pittsburgh, PA, USA. Electronic address: vujanovicnl@msx.upmc.edu.

Publikováno v: Cellular immunology [Cell Immunol] 2014 May-Jun; Vol. 289 (1-2), pp. 119-27. Date of Electronic Publication: 2014 Apr 08.